
Disc Medicine faces class action after FDA rejects drug application, causing stock to drop 22%.
Disc Medicine received a Complete Response Letter from the FDA on February 13, 2026, rejecting its new drug application for bitopertin due to uncertainties requiring more evidence. This news caused the company's stock to fall 22% the same day. The Ro...

